logo
Plus   Neg
Share
Email

5 Top Losers In Healthcare Sector (LQDA, MNK, ENDP...)

pharmadown aug27 lt

The following are some of the healthcare stocks that posted the biggest percentage decline on Tuesday.

1. Liquidia Technologies Inc. (LQDA)

Liquidia is a late-stage clinical biopharmaceutical company developing human therapeutics using its proprietary PRINT technology.

Lost 17.57% to close Tuesday's (Aug.27) trading at $4.55.

News: A SEC filing released on August 26, 2019, shows that Albury Timothy, Senior Vice President and Chief Accounting Officer of the Company, sold 6,762 shares of Liquidia Technologies at an average price of $6.00 per share on August 22nd.

On August 14, he had sold 1,386 shares of Liquidia Technologies at an average price of $6.87 per share.

Clinical Trials & Near-term Catalysts:

The lead drug candidate is LIQ861 for the treatment of pulmonary arterial hypertension. LIQ865 for the treatment of local post-operative pain is another clinical drug candidate.

-- The NDA for LIQ861 for the treatment of pulmonary arterial hypertension is expected to be submitted in late 2019.
-- Completion of toxicology studies that support LIQ865 as a phase 2-ready program is anticipated by the end of the year.

2. Emmaus Life Sciences Inc. (EMMA)

Emmaus Life Sciences, formerly known as "MYnd Analytics, Inc., is a commercial-stage biopharmaceutical company.

Lost 15.14% to close Tuesday's trading at $2.69.

News: No news

Upcoming event:

On July 18, 2019, Emmaus common stock began trading on The Nasdaq Capital Market under the symbol "EMMA."

Emmaus is currently reviewing a number of options related to maintaining the listing of its common stock on The Nasdaq Capital Market. The Company has appealed the initial decision of the Listing Qualifications Staff of The Nasdaq Stock Market LLC.
The appeal is scheduled to be heard on September 5, 2019. In the event the appeal is unsuccessful, Emmaus common stock may be eligible for quotation on the OTC Market.

3. Mallinckrodt Public Limited Company (MNK)

Mallinckrodt is a global biopharmaceutical company.

Lost 15.64% to close Tuesday's trading at $3.56.

News: The U.S. Court of Appeals for the Federal Circuit has upheld a Federal District Court's decision rejecting Mallinckrodt's patent infringement lawsuit against Praxair Inc.'s generic version of Inomax.

Mallinckrodt's INOmax is used in combination with artificial ventilation and other medicines to help improve blood oxygen levels in newborn babies with breathing problems associated with pulmonary hypertension and patients of all ages who are undergoing or have undergone heart surgery and develop pulmonary hypertension.

The lawsuit dates back to 2015 when Mallinckrodt filed a suit against Praxair when the latter filed an application with the FDA seeking approval for its generic version of Inomax.

The Federal District Court, in 2017, ruled in favor of Praxair that the patents covering Mallinckrodt's Inomax were invalid. Mallinckrodt appealed the Federal District Court's ruling. But now the Appeals Court has also ruled in favor of Praxair.

Praxair's generic version of Inomax secured FDA approval last October but is yet to be launched.

4. Endo International plc (ENDP)

Endo International is a generics and specialty branded pharmaceutical company.

Lost 12.37% to close Tuesday's trading at $2.55.

News: No news

Recent event

On August 20, 2019, the Company announced that it has reached a settlement in principle with two Ohio counties - the County of Cuyahoga, Ohio, the County of Summit, Ohio - and certain related persons to resolve Track 1 opioid cases.
As part of the settlement, Endo will pay a total sum of $10 million and will provide up to $1 million of its Vasostrict and Adrenalin products free of charge to the two Ohio counties to be used in their sole discretion.

5. Salarius Pharmaceuticals Inc. (SLRX)

Salarius Pharma is a clinical-stage oncology company targeting the epigenetic causes of cancers.

Lost 11.31% to close Tuesday's trading at $10.82.

News: No news

Recent events:

-- On August 26, 2019, the Company entered into a collaborative partnership with the Ivy Brain Tumor Center at the Barrow Neurological Institute to test Salarius' therapeutic candidate, Seclidemstat, for the treatment of glioblastoma. The news sent the stock up over 20% that day.

Seclidemstat is the lead drug candidate of Salarius and is currently being tested in a Phase 1 study for refractory or relapsed Ewing's sarcoma and a Phase 1 study for Advanced Solid Tumors.

-- On January 4, 2019, privately-held Salarius merged with public-listed Flex Pharma Inc., and the combined company was renamed Salarius Pharmaceuticals Inc.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT